Results 231 to 240 of about 2,899,588 (264)

Role of HER2 in Response to Neoadjuvant Endocrine Therapy in Luminal Breast Cancer. [PDF]

Curr Oncol
Monte CD, Martí C, Rodríguez E, Moreno-Palacios E, Frías L, Meléndez M, Loayza A, Yébenes L, Sánchez-Méndez JI.   +8 more
europepmc   +1 more source

A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy

Advanced Science, EarlyView.
Chronic metabolic stress is a major contributor to HFpEF progression. Under prolonged metabolic stress, Pak1 activity becomes impaired, contributing to disrupted ER proteostasis, cardiomyocyte apoptosis, fibrosis, and diastolic dysfunction. Mechanistically, Pak1 overexpression activates the ERK1/2–MNK1–eIF4E signaling axis, promotes translational ...
Honglin Xu, Hongyuan Zhang, Tayyiba Azam, Susanne S. Hille, Yingjuan Liu, Min Zi, Jiaqing Lang, He Yu, Yujia Cao, Bernard D. Keavney, Tamer M. A. Mohamed, Jessica M. Miller, Riham R. E. Abouleisa, Ming Xu, Elizabeth J. Cartwright, Oliver J. Müller, Ming Lei, Xin Wang   +17 more
wiley   +1 more source

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition). [PDF]

Transl Breast Cancer Res
Yuan Y, Yin Y, Wang S, Liu Y, Yang J, Yan M, Mo X, Pan Y, Wang X, Wang H, Li J, Wang S, Wu J, Song E, Jiang Z, Chinese Consensus Group on Breast Cancer Endocrine Therapy.   +15 more
europepmc   +1 more source

Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation

Advanced Science, EarlyView.
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun, Hengjie Xu, Sheng Yang, Jiahui Zhou, Chuanxin Tian, Hongxu Nie, Chi Jin, Tuo Wang, Zhihao Chen, Junwei Tang, Yifei Feng, Xiaowei Wang, Yueming Sun   +12 more
wiley   +1 more source

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk. [PDF]

J Transl Med
Quagliariello V, Berretta M, Bisceglia I, Barbato M, Arianna R, Forte P, Santagata J, Maurea C, Canale ML, Paccone A, Inno A, D'Ambrosio C, Oliva S, Dessalvi CC, Di Matola T, Gabrielli D, Maurea N.   +16 more
europepmc   +1 more source

SemanticST: A Scalable Multi‐Contextual Graph Learning Framework for Uncovering Spatial Niches and Robust Multi‐Sample Integration in Spatial Transcriptomics

Advanced Science, EarlyView.
Technical limitations often let dominant signals overshadow rare cell types and fine‐grained heterogeneity in spatial transcriptomics. SemanticST, a graph neural network using multi‐semantic graph fusion and a novel min‐cut loss, recovers these subtle patterns.
Roxana Zahedi, Ahmadreza Argha, Nona Farbehi, Ivan Bakhshayeshi, Thantrira Porntaveetus, Youqiong Ye, Nigel H. Lovell, Hamid Alinejad‐Rokny   +7 more
wiley   +1 more source

Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer. [PDF]

Histopathology
Grosse C, Grosse A, Noack P, Preuss CI, Schwarz HK, Schneeweiss B, Gitter T, Schrenk P, Langer R.   +8 more
europepmc   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source

Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer. [PDF]

J Breast Cancer
Koh JH, Hong Y, Sim EJ, Sung S, Lim W, Lee HB, Moon HG, Han W, Park SK, Korean Breast Cancer Society.   +9 more
europepmc   +1 more source

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. [PDF]

Curr Oncol
Abdel-Razeq H, Sharaf B.
europepmc   +1 more source